Compare Lockheed Martin Corporation (LMT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Summit Therapeutics Inc — how do they compare? Lockheed Martin Corporation trades at $507 (market cap $117.48B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Lockheed Martin Corporation is far larger — about 11.2× Summit Therapeutics Inc's market cap, and Lockheed Martin Corporation pays a 2.71% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LMT | SMMT | |
|---|---|---|
Market Cap | $117.48B | $10.48B |
Sector | Industrials | Health |
52-Week High | $676.70 | $29.32 |
52-Week Low | $410.74 | $13.05 |
Enterprise Value | $136.28B | $9.90B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $507.09, down 0.33% on the day, with a bearish technical signal but strong analyst consensus. Recent earnings show mixed results with Q3 2025 beating estimates but subsequent quarters missing. The company reported 2025 revenue of $75.05B and net income of $5.02B, with a P/E of 24.68. News highlights include the launch of a lower-cost Patriot missile and collaborations in space technology, reflecting strategic moves to address cost pressures and growth opportunities.
LMT presents a bullish long-term outlook with a consensus price target of $614, representing 21% upside, supported by a strong defense backlog and space economy potential. Risks include margin compression from cost-cutting initiatives, hypersonic missile delays, and competitive threats from low-cost defense startups. Investor sentiment is cautiously optimistic, balancing near-term earnings volatility against strategic positioning in high-growth defense sectors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
